ADAG vs ZLAB vs LEGN vs ZYME

For growth investors, Legend Biotech Corporation (LEGN) is the stronger pick with 64.

0% revenue growth year-over-year, versus -99. 4% for Adagene Inc. (ADAG). Analysts rate Adagene Inc. (ADAG) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Legend Biotech Corporation (LEGN) delivered a total return of -11.

3%, compared to -90. 0% for Zai Lab Limited (ZLAB). Over 10 years, the gap is even starker: ZYME returned +76. 0% versus ADAG's -88. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Legend Biotech Corporation (LEGN) is the lower-risk stock at 0.

70β versus Zai Lab Limited's 1. 15β — meaning ZLAB is approximately 63% more volatile than LEGN relative to the S&P 500. On balance sheet safety, Zymeworks Inc. (ZYME) carries a lower debt/equity ratio of 7% versus 41% for Legend Biotech Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Legend Biotech Corporation (LEGN) is pulling ahead at 64.

0% versus -99. 4% for Adagene Inc. (ADAG). On earnings-per-share growth, the picture is similar: Zai Lab Limited grew EPS 38. 5% year-over-year, compared to -75. 9% for Adagene Inc.. Over a 3-year CAGR, LEGN leads at 106. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Legend Biotech Corporation (LEGN) is the more profitable company, earning -28.

8% net margin versus -323. 9% for Adagene Inc. — meaning it keeps -28. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LEGN leads at -13. 3% versus -348. 4% for ADAG. At the gross margin level — before operating expenses — ZYME leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Zymeworks Inc.

(ZYME) trades at 15. 5x forward P/E versus 393. 3x for Legend Biotech Corporation — 377. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ZLAB: 105. 0% to $35. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Legend Biotech Corporation (LEGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

70)). Both have compounded well over 10 years (LEGN: -3. 1%, ZLAB: -38. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ADAG is a small-cap quality compounder stock; ZLAB is a small-cap high-growth stock; LEGN is a small-cap high-growth stock; ZYME is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.